CFO of Repligen Corp (30-Year Financial, Insider Trades) Jon Snodgres (insider trades) sold 15,394 shares of RGEN on 05/13/2020 at an average price of $128.74 a share. The total sale was $2 million.
Repligen Corp is a bioprocessing company developing, producing and commercializing biologic drugs. The company offers its products to life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen Corp has a market cap of $7.35 billion; its shares were traded at around $140.48 with a P/E ratio of 312.18 and P/S ratio of 25.42. Repligen Corp had annual average EBITDA growth of 19.90% over the past five years. GuruFocus has detected 2 severe warning signs with Repligen Corp. .
CFO Recent Trades:
- CFO Jon Snodgres sold 15,394 shares of RGEN stock on 05/13/2020 at the average price of $128.74. The price of the stock has increased by 9.12% since.
Directors and Officers Recent Trades:
- Senior VP, R&D Ralf Kuriyel sold 8,000 shares of RGEN stock on 05/13/2020 at the average price of $127.8. The price of the stock has increased by 9.92% since.
- Director Nicolas Barthelemy sold 2,688 shares of RGEN stock on 04/22/2020 at the average price of $109.99. The price of the stock has increased by 27.72% since.
- Director Karen A Dawes sold 12,200 shares of RGEN stock on 04/20/2020 at the average price of $104.57. The price of the stock has increased by 34.34% since.
For the complete insider trading history of RGEN, click here
.
